Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2015

Govindan Ramaswamy, Mandrekar Sumithra J, Gerber David E, Oxnard Geoffrey R, Dahlberg Suzanne E, Chaft Jamie, Malik Shakun, Mooney Margaret, Abrams Jeffrey S, Jänne Pasi A, Gandara David R, Ramalingam Suresh S, Vokes Everett E

Abstract excerpt

The treatment of patients with metastatic non-small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment based on specific molecular alterations. Despite this 10-year evolution, targeted therapies have not been studied adequately in patients with resected NSCLC who have clearly defined actionable mutations. The advent of next-generation sequencing has now...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Gene Rearrangement

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Receptor Protein-Tyrosine Kinases

Share to Research Design

Source

Open in PubMed Open full text

Identifiers

PMID: 26672084
DOI: 10.1158/1078-0432.CCR-15-0354
PMCID: PMC4683399

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.PMID 26672084Read ↗

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.Semantic proximity Read ↗

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.Semantic proximity Read ↗

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted TherapiesSemantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.Semantic proximity Read ↗

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Semantic proximity Read ↗

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.Semantic proximity Read ↗

Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.Semantic proximity Read ↗

The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).Semantic proximity Read ↗

How and when to use genetic markers for nonsmall cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.